Research Topics
| Monica L GuzmanSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Preferential induction of apoptosis for primary human leukemic stem cellsMonica L Guzman
Blood and Marrow Transplant Program, Markey Cancer Center, Division of HematologyOncology, University of Kentucky Medical Center, Lexington, KY 40536-0093 USA
Proc Natl Acad Sci U S A 99:16220-5. 2002..Further, the data begin to elucidate the molecular mechanisms that underlie LSC-specific apoptosis and suggest new directions for AML therapy...- The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
Blood 105:4163-9. 2005..On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy... - Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Monica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4436-44. 2007..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations... - Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataDuane C Hassane
James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
Blood 111:5654-62. 2008..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets... - Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolideJolanta Skalska
James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
PLoS ONE 4:e8115. 2009..Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols... - An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4427-35. 2007..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo... - Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biologyMonica L Guzman
James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
Cancer Cell 15:252-4. 2009..In the current issue of Cancer Cell, a study by Santaguida et al. provides new insights into JunB's function and the genesis of myeloid disease... - Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cellsJonathan M Weber
Endocrine Division, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue Box 693 Rochester, NY 14642, USA
Bone 39:485-93. 2006.... - Mechanisms controlling pathogenesis and survival of leukemic stem cellsCraig T Jordan
Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 703, NY 14642, USA
Oncogene 23:7178-87. 2004..In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells... - Cancer stem cellsCraig T Jordan
James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
N Engl J Med 355:1253-61. 2006 - Feverfew: weeding out the root of leukaemiaMonica L Guzman
Expert Opin Biol Ther 5:1147-52. 2005..Thus, this naturally occurring agent may provide new avenues of investigation for the treatment of leukaemia. In this article, characteristics of parthenolide are reviewed... - Considerations for targeting malignant stem cells in leukemiaMonica L Guzman
Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology/Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA
Cancer Control 11:97-104. 2004..A better understanding of LSC cell and molecular biology will allow the design of more effective therapies... - Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levelsIvan Topisirovic
Institute for Research in Immunovirology and Cancer, University of Montreal, Montreal, Quebec H3T 1J4, Canada
Mol Cell Biol 25:1100-12. 2005.... - The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSaman Hewamana
Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
Blood 111:4681-9. 2008..001, r(2) = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease... - Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesisIvan Topisirovic
Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York University, One Gustave Levy Place, New York, NY 10029, USA
Mol Cell Biol 23:8992-9002. 2003..Thus, our findings indicate that this nuclear function of eIF4E can contribute to leukemogenesis by promoting growth and by impeding differentiation...